A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer's Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice (Q89373218)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

title

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer's Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Yun-Zhou Yu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Si Liu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Hai-Chao Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

DanYang Shi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Qing Xu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Xiao-Wei Zhou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Zhi-Wei Sun

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

Pei-Tang Huang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

publication date

5 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

Journal of Neuroimmune Pharmacology

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

657-668

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

Pathological reorganization of NMDA receptors subunits and postsynaptic protein PSD-95 distribution in Alzheimer's disease

3 April 2020

cites work

1 reference

12 December 2020

Soluble aβ promotes wild-type tau pathology in vivo

1 reference

12 December 2020

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

1 reference

12 December 2020

Amyloid-β induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors.

1 reference

12 December 2020

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

1 reference

12 December 2020

Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice

1 reference

12 December 2020

Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease

1 reference

12 December 2020

Targeting synaptic dysfunction in Alzheimer's disease therapy.

1 reference

12 December 2020

Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies

1 reference

12 December 2020

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease

1 reference

12 December 2020

Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

1 reference

12 December 2020

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

1 reference

12 December 2020

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

1 reference

12 December 2020

AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly

1 reference

12 December 2020

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

1 reference

12 December 2020

Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy

1 reference

12 December 2020

Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice

1 reference

12 December 2020

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

1 reference

12 December 2020

Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease

1 reference

12 December 2020

Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis

1 reference

12 December 2020

Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice

1 reference

12 December 2020

Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology

1 reference

12 December 2020

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

1 reference

12 December 2020

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

1 reference

12 December 2020

Calpain inhibition as a potential treatment of Alzheimer's disease

1 reference

12 December 2020

Vaccination as a therapeutic approach to Alzheimer's disease.

1 reference

12 December 2020

Amyloid-ß-directed immunotherapy for Alzheimer's disease

1 reference

12 December 2020

Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease

1 reference

12 December 2020

Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing.

1 reference

12 December 2020

Murine models of Alzheimer's disease and their use in developing immunotherapies.

1 reference

12 December 2020

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

1 reference

12 December 2020

Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease.

1 reference

12 December 2020

beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons.

1 reference

12 December 2020

IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology

1 reference

12 December 2020

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

1 reference

12 December 2020

Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum.

1 reference

12 December 2020

β-Amyloid oligomers in aging and Alzheimer's disease

1 reference

12 December 2020

TAU Aggregation is a Therapeutic Target for Alzheimers Disease

1 reference

12 December 2020

Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells.

1 reference

12 December 2020

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

12 December 2020

Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins

1 reference

12 December 2020

The role of amyloid β in the pathogenesis of Alzheimer's disease

1 reference

12 December 2020

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

1 reference

12 December 2020

Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

1 reference

12 December 2020

Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment

1 reference

12 December 2020

Dynamin 1 is required for memory formation

1 reference

12 December 2020

The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons.

1 reference

12 December 2020

Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction

1 reference

12 December 2020

Synaptic changes in Alzheimer's disease and its models

1 reference

12 December 2020

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

1 reference

12 December 2020

Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model

1 reference

12 December 2020

A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer's disease

1 reference

12 December 2020

10.1007/S11481-016-9678-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27147259 AND SRC:MED&resulttype=core&format=json

3 April 2020

1 reference